India's OPPI Urges DoP to Reconsider Price Regulation on APIs

OPPI urges the reconsideration of para 4(2) recommendation that price regulation would not apply to any upstream products such as bulk drugs and intermediates.

The Organisation of Pharmaceutical Producers of India (OPPI) has urged the department of pharmaceuticals (DoP) to reconsider its decision to bring bulk drugs and intermediates out of the purview of price control in the National Pharmaceutical Pricing Policy 2011 (NPPP 2011).

OPPI urges the reconsideration of para 4(2) recommendation that price regulation would not apply to any upstream products such as bulk drugs and intermediates. The Organisation has a strong apprehension that there will be a significant increase in prices of bulk drugs/APIs after their price controls are lifted. Moreover, there will be a time lag between increase in cost of bulk drugs/APIs used as inputs for finished formulations and the price neutralization of input costs can only be taken at the end of the financial year based on price index.